DCM
RPRX icon

Dupont Capital Management’s Royalty Pharma RPRX Stock Holding History

Dupont Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,487
Closed -$415K – 1825
2021
Q3 		$415K Hold
11,487
– – 0.01% 959
2021
Q2 		$471K Buy
+11,487
New +$489K 0.01% 1034

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dupont Capital Management's RPRX Position: Q4 2021 in Review

Dupont Capital Management sold out of Royalty Pharma (RPRX) in Q4 2021, closing a stake of 11,487 shares — an estimated $415K sold.

Dupont Capital Management first reported a position in RPRX in Q2 2021 and held it in 2 quarters. The position peaked at $471K in Q2 2021. 266 funds tracked by Wall St. Rank hold RPRX as of Q4 2021.

  • Dupont Capital Management reported no remaining Royalty Pharma position as of Q4 2021 after selling out during the quarter.
  • Dupont Capital Management sold 11,487 Royalty Pharma shares in Q4 2021, an estimated $415K.
  • Dupont Capital Management first reported a position in Royalty Pharma in Q2 2021 and held it in 2 quarters.
  • Dupont Capital Management's Royalty Pharma position peaked at $471K in Q2 2021.
  • 266 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2021.

Based on Dupont Capital Management's 13F filing for Q4 2021, filed 31 Jan 2022.